| [1] Standards of medical care in diabetes——2014[J]. Diabetes Care, 2014, 37(Suppl 1):S14-S80.[2] Lewis EJ, Greene T, Spitalewiz S, et al. Pyridorin in type 2 diabetic nephropathy[J]. J Am Soc Nephrol, 2012, 23(1):131-136.[3] Ashcroft FM, Rorsman P. Diabetes mellitus and the β cell:the last ten years[J]. Cell, 2012, 148(6):1160-1171.[4] Wang L, Li J, Li D. Losartan reduces myocardial interstitial fibrosis in diabetic cardiomyopathy rats by inhibiting JAK/STAT signaling pathway[J]. Int J Clin Exp Pathol, 2015, 8(1):466-473.[5] Zhou X, Liu W, Gu M, et al. Helicobacter pylori infection causes hepatic insulin resistance by the c-Jun/miR-203/SOCS3 signaling pathway[J]. J Gastroenterol, 2015, 50(10):1-14.[6] Guay C, Regazzi R. Circulating microRNAs as novel biomarkers for diabetes mellitus[J]. Nat Rev Endocrinol, 2013, 9(9):513-521.[7] Xu G, Yang F, Ding CL, et al. MiR-221 accentuates IFN's anti-HCV effect by downregulating SOCS1 and SOCS3[J]. Virology, 2014, 462-463C(1):343-350.[8] Kokil GR, Veedu RN, Ramm GA, et al. Type 2 diabetes mellitus:limitations of conventional therapies and intervention with nucleic acid-based therapeutics[J]. Chem Rev, 2015, 115(11):4719-4743.[9] Yin RV, Phung OJ. Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus[J]. Nutr J, 2015, 14(1):14.[10] Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death[J]. N Engl J Med, 2011, 364(9):829-841.[11] Barutta F, Bruno G, Grimaldi S, et al. Inflammation in diabetic nephropathy:moving toward clinical biomarkers and targets for treatment[J]. Endocrine, 2015, 48(3):730-742.[12] Guay C, Roggli E, Nesca V, et al. Diabetes mellitus, a microRNA-related disease?[J]. Transl Res, 2011, 157(4):253-264.[13] Dangwal S, Stratmann B, Bang C, et al. Impairment of wound healing in patients with type 2 diabetes mellitus influences circulating microRNA patterns via inflammatory cytokines[J]. Arterioscler Thromb Vasc Biol, 2015, 35(6):1480-1488.[14] Chung AC, Huang XR, Meng X, et al. miR-192 mediates TGF-beta/Smad3-driven renal fibrosis[J].J Am Soc Nephrol,2010,21(8):1317-1325.[15] Xiong M, Jiang L, Zhou Y, et al. The miR-200 family regulates TGF-β1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression[J]. Am J Physiol Renal Physiol, 2012, 302(3):F369-F379. |
